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Editorial
Implantable Device Prescription in 2004: A Complex Business?
CHU-PAK LAU
From Cardiology Division, The University of Hong Kong, Queen Mary Hospital, Hong Kong

Implantable devices are now used to treat
patients with congestive heart failure (CHF) with
electromechanical in dyssynchrony. 1-4 The proven
benefits include improvement in cardiovascular
functional state such as better exercise capacity,
6 min-hallwalk distance, New York Heart
Association Class and quality of life. There is also
measurable structural change in reverse left
ventricular (LV) remodelling. 5 These lead to
combined clinical benefit of reduced hospitalisation
and possibly reduced mortality. On the other hand,
patients with CHF has a high risk of concomitant
arrhythmias, and sudden cardiac death is an important
cause of mortality in these patients. 6 Prophylactic
implantable cardioverter defibrillator (ICD) has been
shown to improve survival over best medical therapy
when implanted either for primary or secondary
prevention. 7-8 Thus when a device is prescribed for
any patients, one must consider these therapeutic
options so that the patient can derive the maximum
benefit from an optional device. Upgrading a device
is not only costly, but can be difficult because of
access issues and complexity of multiple leads.

Congestive Heart Failure
In patients with a QRS >120 ms and poor
ejection fraction (EF, <35%), cardiac
resynchronisation therapy (CRT) is now a Class IIa
indication for pacing. The main argument here is
whether to use a CRT or a CRT with ICD backup
(CRT-D) in the CHF population with high risk of
SCD. 9 The pros would advocate a one-off device
treatment which is evidenced based 8-9 both for
ischaemic and non-ischaemic cardiomyopathy. In
addition, most benefits of ICD are in patients with
wide an underlying QRS complex. The antagonist
would argue the relative small benefit of ICD over
drug therapy (e.g. 106 vs 97 deaths in the drug vs
ICD arms in MADIT 2). In addition, many CHF
patients have significant co-morbidities that would
limit the lifespan of these individuals, and CRT alone
would give good clinical relief and reduce
hospitalisation. Cost is an important issue in all
countries. In patients with narrow QRS complex,
underlying LV dyssynchrony may be present, and
these patients may also benefit from CRT, although
we do not yet have trial data.

Bradycardia Pacing
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Existing studies with the exception of a
proportion of patients in MUSTIC1 do not include a
group of patients with right ventricular (RV) pacing,
which induces a wide QRS complex. Whether one
can extrapolate existing short to intermediate
term data to these patients remain controversial
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particularly for patients – who are not symptomatic
of heart failure. For patients with sick sinus
syndrome, it may be fair to apply the current
indication for CRT in these patients if conconcomitant LBBB and CHF are present. In patients
with complete atrioventricular (AV) block, the
situation is a little more complex. A LV based pacing
system after AV nodal ablation gives a better acute
haemodynamic results compared to RV pacing. 10
There is less mitral regurgitation and better ejection
fraction after LV pacing compared to RV pacing. The
data also suggest similar benefit in patients with
either preserved or impaired EF. These data have
implication of the use of CRT rather than RV pacing
after AVN ablation. There is as yet no data for
idopathic AV block. Whether one should implant a
CRT device in AV block remains controversial and
it is uncertain if a CRT-D should be used in those
with poor EF. RV apical pacing is associated with
long term impairment of LV function and regional
perfusion defects, and RV septal pacing may be an
alternative way to preserve LV function.11

Conclusion
We are now at a crossroad when prescribing a
device for a patient with combination of brady or
tachyarrhythmias with poor LV function. For most
patients, a single, most sophisticated device that fit
all purpose is clearly appealing, but there are issues
in risk of procedure, cost and complexity in
programming. We clearly need data to best tailor
therapy for the individual patient to minimize the
need for system change, and yet medically, socially,
and economically acceptable.
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